|Bid||287.00 x 1000|
|Ask||305.00 x 900|
|Day's Range||295.00 - 298.38|
|52 Week Range||249.17 - 370.57|
|PE Ratio (TTM)||21.16|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CAMBRIDGE, Mass., June 19, 2018-- Biogen today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018. The live webcast will ...
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / U.S. markets finished mostly lower on Monday, with the Dow logging its 5th straight decline, on fears of growing trade tensions between the U.S. and China. The ...
The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the development of local STEM (science, technology, engineering, and math) education ecosystems in Cambridge and Somerville. The Biogen Foundation’s STAR Initiative is intended to strengthen and support educational offerings in these cities by helping increase access to STEM resources and opportunities for students currently underrepresented in STEM college or career pathways. The six nonprofits selected by the Biogen Foundation will partner with Cambridge and Somerville public schools, focusing on students in grades 6-12.
Samsung Bioepis Co., Ltd. and Biogen (BIIB) today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™ (SB2, infliximab biosimilar), and IMRALDI™ (SB5, adalimumab biosimilar) – which will be presented at the Annual European Congress of Rheumatology (EULAR 2018) held June 13–16 in Amsterdam, Netherlands. “Since BENEPALI and FLIXABI launched more than two years ago, they have played an increasingly important role in widening access to life-enhancing treatment options for patients and healthcare systems across Europe,” said Chul Kim, Head of Clinical Sciences Division, Samsung Bioepis.
Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA® (nusinersen) Study presented examines neurofilament (pNF-H) as a potential ...
Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA ® Study presented examines neurofilament as a potential biomarker for ...
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Alkermes PLC (NASDAQ: ALKS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALKS as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has received a $50 million payment from Biogen, Inc. (NASDAQ: BIIB), following the latter's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (formerly known as ALKS 8700), which is an oral fumarate in Phase-3 development for the treatment of relapsing forms of multiple sclerosis (MS).
CAMBRIDGE, Mass., June 07, 2018 (GLOBE NEWSWIRE) -- Biogen (BIIB) announced today it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4 million and an additional $18 million payment if Biogen exercises its option, with up to $335 million in potential development and commercialization milestones as well as tiered royalties. This unique combination could position TMS-007 as a best in class thrombolytic for individuals with acute ischemic stroke (AIS) with potential for an extended treatment window as compared to current thrombolytic agents.
Biogen (BIIB) announced today it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4 million and an additional $18 million payment if Biogen exercises its option, with up to $335 million in potential development and commercialization milestones as well as tiered royalties.
CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it closed its expanded strategic collaboration with Biogen (BIIB) to discover and develop novel antisense drugs for a broad range of neurological diseases following receipt of clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. Biogen paid Ionis $1 billion in cash, which included $625 million for the purchase of 11,501,153 shares of Ionis common stock at a price of $54.34 per share and a $375 million upfront payment. On April 20, 2018, Ionis and Biogen announced they would expand their strategic collaboration to develop novel antisense drugs for a broad range of neurological diseases through a new ten-year collaboration.
WOODCLIFF LAKE, N.J. and CAMBRIDGE, Mass., June 5, 2018 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (Aβ) levels in the brain measured by amyloid-PET (positron emission tomography). A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant.
Karp will lead the newly created Corporate Development function, which will include corporate and business development and corporate strategy. "We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience," Vounatsos said.
Karp will lead the newly created Corporate Development function, which will include corporate and business development and corporate strategy. “We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience,” Vounatsos said.
This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: AveXis Inc. (NASDAQ: AVXS), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd, (NYSE: BHVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): All you have to do is sign up today for this free limited time offer by clicking the link below. On Tuesday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 941,320 shares, which was above their three months average volume of 884.73 thousand shares. The Company's shares have gained 88.91% over the previous three months and 181.89% in the past twelve months.
Biogen and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.
Stock Monitor: Biogen Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on Galapagos N.V. (NASDAQ: GLPG ). If you want access ...
NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Biogen Inc. (NASDAQ: BIIB ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 8:30 AM Eastern Time. To listen ...
Biogen (BIIB) today announced new findings detailing the benefits that SPINRAZA® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as increased survival for the most severely affected. “These results reinforce SPINRAZA’s unprecedented and compelling efficacy across a broad range of SMA populations, enabling patients to improve mobility and motor function – and, for the most severely affected, increase their chances of survival,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. The SHINE analysis reported interim results as of June 30, 2017, from the open-label extension study for patients (n=89) with infantile-onset SMA (most likely to develop Type 1) who transitioned from the Phase 3 ENDEAR study.
Biogen and Ionis Pharmaceuticals announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
Biogen announced it will present data from its portfolio of marketed treatments and clinical development programs for some of the most complex and difficult-to-treat neurodegenerative diseases at the 70th annual meeting of the American Academy of Neurology in Los Angeles .
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Biogen Inc. and its partner Samsung Bioepis announced today an agreement with AbbVie for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® .
Biogen Inc. today announced it will report first quarter 2018 financial results on Tuesday, April 24, 2018, before the financial markets open.